Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis

Chandana B Herath, Fiona Jane Warner, John S Lubel, Rachel G Dean, Zhiyuan Jia, Rebecca Ann Lew, Alexander Ian Smith, Louise M Burrell, Peter W Angus

Research output: Contribution to journalArticleResearchpeer-review

133 Citations (Scopus)


BACKGROUND/AIMS: Angiotensin-converting enzyme 2 (ACE2), its product, angiotensin-(1-7) and its receptor, Mas, may moderate the adverse effects of angiotensin II in liver disease. We examined the expression of these novel components of the renin angiotensin system (RAS) and the production and vasoactive effects of angiotensin-(1-7) in the bile duct ligated (BDL) rat. METHODS: BDL or sham-operated rats were sacrificed at 1, 2, 3 and 4 weeks. Tissue and blood were collected for gene expression, enzyme activity and peptide measurements. In situ perfused livers were used to assess angiotensin peptide production and their effects on portal resistance. RESULTS: Hepatic ACE2 gene and activity (P
Original languageEnglish
Pages (from-to)387 - 395
Number of pages9
JournalJournal of Hepatology
Issue number3
Publication statusPublished - 2007

Cite this